Aims: The present study aims to investigate the role of Akt in the regulation of urinary bladder organ hypertrophy caused by partial bladder outlet obstruction (pBOO). Main methods: Male rats were surgically induced for pBOO. Real-time PCR and western blot were used to examine the levels of mRNA and protein. A phosphoinositide 3-kinase (PI3K) inhibitor LY294002 was used to inhibit the activity of endogenous Akt. Key findings: The urinary bladder developed hypertrophy at 2 weeks of pBOO. The protein but not mRNA levels of type I collagen and α-smooth muscle actin (αSMA) were increased in pBOO bladder when compared to sham control. The phosphorylation (activation) levels of Akt1 (p-Ser 473 ), mammalian target of rapamycin (mTOR), p70S6 kinase (p70S6K), and 4E-BP1 were also increased in pBOO bladder. LY294002 treatment reduced the phosphorylation levels of Akt1 and 4E-BP1, and the protein levels of type I collagen and αSMA in pBOO bladder. The mRNA and protein levels of proliferating cell nuclear antigen (PCNA) were increased in pBOO bladder, and PCNA up-regulation occurred in urothelial not muscular layer. LY294002 treatment had no effect on the mRNA and protein levels of PCNA in pBOO bladder. LY294002 treatment partially reduced the bladder weight caused by pBOO. Significance: pBOO-induced urinary bladder hypertrophy is attributable to fibrosis, smooth muscle cellular hypertrophy, and urothelium cell hyper-proliferation. Akt1-mediated protein synthesis in pBOO bladder contributes to type I collagen and αSMA but not PCNA up-regulation. Target of Akt1 is necessary but not sufficient in treatment of urinary bladder hypertrophy following pBOO.
Introduction
Bladder wall thickening occurs in many diseases and disorders in humans and animals suffering from bladder inflammation ( [1, 2] , neurological impairment [3] , lower urinary tract obstruction [4] [5] [6] [7] , or as a natural effect of aging [8] . In clinical studies, bladder wall thickness is considered as a non-invasive and effective test to evaluate patients with lower urinary tract obstruction, and is suggested to be useful for showing the effectiveness of drug treatment [5] . Bladder wall thickening is manifested by multiple factors including but not limit to alterations of urothelium metabolic properties, inflammatory responses, fibrosis, and detrusor muscle remodeling [9] [10] [11] [12] [13] [14] . Understanding of the molecular changes in the thickened bladder wall can provide fundamental information in guiding the development of drugs for treatment.
Experimental pBOO in animals including rats, mice, rabbits, and guinea pigs results in increases in bladder weight and bladder wall thickening. In rats, the bladder weight is increased one week following pBOO induction [15] . At 6 weeks, the protein content and gene expression of type I and type III collagen are increased in the hypertrophic urinary bladder ( [9, 16] . In guinea pigs, the bladder weight and DNA content are not changed at one week, but are increased at 2, 4, and 8 weeks after obstruction, with transient increases in the mRNA levels of c-fos and c-Myc at 2 weeks [17] . In rabbit and mice, bladder obstructed for 2 weeks showed smooth muscle cellular hypertrophy [18, 19] . To have a complete understanding of the regulation of bladder organ hypertrophy following pBOO, we aim to examine the expression levels of type I collagen, α-smooth muscle actin (αSMA) and proliferating cell nuclear antigen (PCNA) in the urinary bladder at 2 weeks following pBOO. Type I collagen is the most abundant collagen responsible for forming extracellular matrix in skin, tendon, vascular, organs, and bone, and its increase is one of the major factors contributing to fibrosis [20, 21] . αSMA is the predominate isoform of actin within smooth muscle and takes up a substantial portion of the volume of the cytoplasm of smooth muscle cells [22] . The ratio of αSMA to nuclear protein implicates cellular hypertrophy [23] . PCNA as a scaffold protein is critical for DNA replication, DNA repair, chromatin remodeling and epigenetics, and cell proliferation [24] . Therefore, examination of changes in type I collagen, αSMA and PCNA in the urinary bladder will suggest factors that contribute to bladder wall thickening following pBOO.
Protein production in the urinary bladder relies on the transcriptional and translational activities. In control of protein synthesis, the phosphoinositide 3-kinase (PI3K)/Akt pathway is essential, which mediates the phosphorylation (activity) of mammalian target of rapamycin (mTOR), phosphorylation and activation of p70S6 kinase (p70S6K), and/or phosphorylation of translation initiation factor (eIF4E)-binding proteins (4E-BP), key components in protein translational machinery ( [25] [26] [27] . The PI3K/Akt pathway can also regulate gene transcription by phosphorylating a number of transcription factors [28] . In our study of inflammation-induced urinary bladder hypertrophy, endogenous nerve growth factor-induced type I collagen protein production is correlated with an activation of Akt1 in the urinary bladder [1] . Akt1 phosphorylation is increased in the urinary bladder of patients with bladder outlet obstruction [29] , and is also regulated by insulin in the urinary bladder of high-fat diet-fed mice [30] . It is not known whether activation of Akt1 directly participates in gene transcription and/or protein production in the hypertrophic urinary bladder following pBOO.
The present study is undertaken to characterize the role of Akt in urinary bladder hypertrophy by regulating the expression levels of type I collagen, αSMA and PCNA. The differential role of Akt in the regulation of protein synthesis and gene transcription, and the partial effectiveness of Akt inhibition in reducing bladder hypertrophy suggest a necessary but not sufficient role of Akt as a therapeutic target in treatment of bladder hypertrophy following pBOO.
Method

Animals
Adult male Sprague-Dawley rats (150-200 g) were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN). All experimental protocols involving animal use in this study were approved by the Institutional Animal Care and Use Committee in Virginia Commonwealth University. Animal care was in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and National Institutes of Health guidelines. All efforts were made to minimize the potential for animal pain, stress or distress as well as to reduce the number of animals used.
Surgery
We created pBOO by surgery. The urinary bladder was exposed via a midline abdominal incision under isoflurane (2.5%) anesthesia. A catheter (outside diameter 1 mm) was placed adjacent to the urethra just distal to the bladder neck. A 4-0 non-absorbable suture was tied around the urethra and catheter, after which the catheter was carefully removed, and the incision was closed. Animals were housed for postsurgery recovery for 2 weeks, and those who had developed bladder hypertrophy were used for this study. A control group underwent a sham operation by exposing the bladder neck but without performing the ligature.
Tissue harvesting
After the animal was weighed, the urinary bladder was freshly dissected out. Excessive liquids inside and outside the bladder were cleaned by autoclaved Kimwipes. The bladder was then weighed. For histology and immunohistochemistry, the urinary bladder was fixed in 4% paraformaldehyde, dehydrated and cryosectioned transversely at a thickness of 8 μm. For western blot, the urinary bladder was homogenized in T-per buffer (Pierce) supplemented with protease (P8340, 1:100, Sigma-Aldrich) and phosphatase inhibitor cocktail 1 (P2850, 1:100, Sigma-Aldrich). For real-time PCR, the urinary bladder was homogenized in RNA extraction buffer (Ambion, TX).
Immunohistochemistry
Cryostat sections were incubated with specific primary antibody of PCNA (1:500, Abcam) followed by secondary antibody conjugated to peroxidase enzyme used for 3,3′-Diaminobenzidine (DAB) stain. A Nikon brightfield microscope equipped with a color camera were used to obtain microscopic photographs. For analysis of PCNA immunoreactivity in the tissue, three random microscopy fields were chosen from each section with caution to avoid field overlap. We focused on the detrusor muscle and urothelium layers. The number of PCNA positive cells in each field was counted. Results were averaged. The size of the area in the microscopic field that contained cells was measured, for the purpose of normalization, with free-tool software installed with the microscopy. The PCNA expression level was expressed as number of immuno-positive cells per mm 2 area.
Western blot
The urinary bladder protein extracts were centrifuged at 20,200g for 10 min at 4°C. The supernatants were removed to a fresh tube for further analysis. The protein concentration was determined using BioRad DC protein assay kit. Proteins were separated on a 7.5-15% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was blocked with 5% milk in Tris-buffered saline for 1 h and then incubated with primary antibodies against phospho-Akt Ser 473 (1:1000, Cell Signaling), phospho-Akt Ser 474 (1:1000, Millipore), phosphomTOR (1:1000, Cell Signaling), phospho-p70 S6K (1:500, Millipore), phospho-4E-BP1 (1:1000, Cell Signaling), total Akt (1:1000, Cell Signaling), αSMA (1:1000, Millipore), type I collagen (1:1000, Cell Signaling), PCNA (1:1000), histone H3 (1:2000, Millipore), and betaactin (β-actin, 1:5000, Sigma). After washing, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody. The bands were identified by ECL-exposed films that were then digitized and performed for densitometric quantification using the software FluorChem 8800 (Alpha Innotech, San Leabdro, CA). The levels of phospho and non-phospho protein of interest were normalized with the level of internal loading controls (i.e. total Akt, β-actin, H3). The expression level of the protein of interest in control animal from each independent experiment was considered as 1, and the relative expression level of the protein of interest in experimental animals was adjusted as a ratio to control animals.
RNA extraction and real-time PCR
Total RNA was extracted using a RNA extraction kit RNAqueous (Ambion, TX). RNA concentration was determined spectrophotometrically. cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, ABI). Real-time PCR was performed using SYBR Green as indicator on StepOnePlus™ Systems (Applied Biosystems, ABI). PCR was carried out for 40 cycles of 95°C for 15 s and 60°C for 1 min. The fluorescence was detected during the reaction, allowing a continuous monitoring of the amount of PCR product. After the PCR reaction, dissociation curve was monitored to verify the specificity of the reaction. The level of target mRNA was normalized against the expression of the internal control 18S, and was calculated with ΔCt method (ΔCt = Ct target gene − Ct internal control in the same sample). The expression level of target mRNA in control group from each independent experiment was considered as 1, and the relative expression level of target mRNA in experimental groups was adjusted as a ratio to its control in each independent experiment and expressed as fold changes (2 −ΔΔCt fold) (ΔΔCt = ΔCt experimental group − ΔCt control group).
Drug treatment
LY294002 (MilliporeSigma-Calbiochem) was dissolved in DMSO as stock and diluted in saline for injection at a dose of 50 μg/kg body weight (i.p.) every fourth day for 2 weeks after induction of pBOO. DMSO as vehicle control was diluted in the same manner as LY294002 was. The diluted DMSO was injected to both sham and pBOO animals for the same amount as and in parallel to LY294002 based on the body weight of the animals. The dose of LY294002 was originally used in our previous studies to inhibit urinary bladder hypertrophy up to 48 h induced by acute inflammation [31] . However, injection of LY294002 to pBOO rats once every 48 h caused severe sickness to animals, possibly due to toxicity. We reduced the frequency of injection to once every four days for a total of 4 injections within the 2-week experimental period. We found that this treatment regime effectively reduced the phosphorylation level of endogenous Akt1 in pBOO rats. Thus we used this dose and frequency for all related experiments.
Statistical analysis
The results from each study were presented as mean ± SD. Comparison between control and experimental groups was made by using Kruskal-Wallis nonparametric one-way ANOVA, or the student's ttest. Differences between means at a level of p ≤ 0.05 were considered to be significant.
Results
Expression of type I collagen, αSMA, and PCNA in the hypertrophic urinary bladder
At 2 weeks post pBOO induction, we measured the weight of the urinary bladder and the body weight of the animals to ensure that the pBOO operation was effective to induce bladder hypertrophy. We found that 5 out 6 rats developed urinary bladder hypertrophy, with one had severe urinary bladder retention which was eliminated from further examination. We focused on the 5 hypertrophic urinary bladder. The 5 sham-operated rats had normal sized urinary bladder. The ratio of the bladder weight to body weight for the hypertrophic urinary bladder was significantly larger (Fig. 1A , p < 0.01) compared to sham-operated control. The ratio of the bladder weight to body weight in shamoperated control and naïve animals had no significant difference. We then measured the thickness of the detrusor wall after H&E stain (Fig. 1B to 1C ) and found that the detrusor wall was also significantly thicker for the hypertrophic urinary bladder when compared to control (Fig. 1D , p < 0.05). To determine the factors that contribute to urinary bladder wall thickening, we compared the mRNA and protein levels of type I collagen, αSMA, and PCNA in the hypertrophic and control urinary bladder.
The protein levels of type I collagen in the hypertrophic urinary bladder were 2.4-fold higher than those in control ( Fig. 2A, western blot; Fig. 2B, protein; p < 0.05) . The mRNA levels of type I collagen in the hypertrophic and control urinary bladder were the same (Fig. 2B,  mRNA) . Since the level of type I collagen is closely related to the degree of fibrosis, we performed trichrome stain of the urinary bladder, which showed an increase in the content of extracellular matrix in pBOO bladder when compared to control (Fig. 2C-D: blue stain) .
The protein levels of αSMA were examined in relative to the levels of nuclear protein histone 3 (H3). We found that the ratio of αSMA/H3 was significantly higher in the hypertrophic urinary bladder (Fig. 3A,  western blot; Fig. 3B , densitometry, p < 0.05). We also found that the mRNA levels of αSMA were not changed in the urinary bladder after pBOO (Fig. 3C) . The up-regulation of αSMA relative to H3 suggested that the content of cytoplasm proteins was greater in the hypertrophic urinary bladder, reflecting cellular hypertrophy [23] . Histological characterization showed that there were fewer smooth muscle cells in normalized area in the hypertrophic urinary bladder compared to control (Fig. 3D-F, arrows indicated nucleus) , which might be due to excessive deposition of extracellular matrix between two cells or the enlargement of cell volume (cellular hypertrophy) due to excessive production of cytoplasm proteins.
To test whether there was hyperplasia and/or urothelium cell hyper-proliferation in the hypertrophic urinary bladder, we examined the mRNA and protein levels of PCNA. We found that there were increases in both the mRNA and proteins levels of PCNA in pBOO bladder when compared to sham control (Fig. 4A -C, p < 0.05). The up-regulation of PCNA was distributed in the urothelium layer (Fig. 4D-F , p < 0.05), not the smooth muscle layer (Fig. 4G-I ).
Increased phosphorylation of Akt and components of protein synthesis in the hypertrophic urinary bladder
Our data that the protein levels but not mRNA levels of type I collagen and αSMA were increased in the hypertrophic urinary bladder suggests a likelihood of an up-regulation of the protein synthesis pathway. We compared the phosphorylation levels of Akt, mTor, p70 S6K , and 4E-BP1 in the hypertrophic and control urinary bladder.
We found that the levels of phospho-Akt Ser 473 (Akt1) but not phosphoAkt Ser 474 (Akt2) was increased in the hypertrophic urinary bladder (Fig. 5 , p < 0.05). One of the major functions of Akt1 is to activate the protein synthesis pathways by phosphorylating mTor. We found that the phosphorylation levels of mTor and its downstream molecules p70 S6K and 4E-BP1 were also up-regulated in the hypertrophic urinary bladder (Fig. 6 , p < 0.05).
Suppression of endogenous Akt phosphorylation by PI3K inhibitor LY294002 reduced the phosphorylation level of 4E-BP1
To examine whether Akt1 indeed activated the protein synthesis pathway in the hypertrophic urinary bladder, we treated the pBOO animals with LY294002 or vehicle control (4 animals for each group). Vehicle (DMSO + saline) treatment did not inhibit pBOO-induced upregulation of Akt1 and 4E-BP1 phosphorylation in the urinary bladder (p < 0.05). LY294002 treatment reduced the phosphorylation level of Akt1 in pBOO bladder when compared to vehicle-treated pBOO (Fig. 7A-B , p < 0.05), suggesting the effectiveness of LY294002 treatment in reducing the endogenous Akt phosphorylation level. LY294002 treatment also reduced the phosphorylation level of 4E-BP1 in the hypertrophic urinary bladder (Fig. 7C-D , p < 0.05), suggesting the involvement of PI3K/Akt in mediating the activity of 4E-BP1 thereby protein synthesis.
LY294002 treatment on the expression levels of type I collagen, αSMA, PCNA, and bladder weight
Vehicle treatment did not inhibit pBOO-induced up-regulation of type I collagen, αSMA and PCNA in the urinary bladder (p < 0.05).
LY294002 treatment reduced the protein levels of type I collagen (Fig. 8A, B , p < 0.05) and αSMA (Fig. 8A , C, p < 0.05) in the pBOO bladder when compared to vehicle-treated pBOO. LY294002 treatment did not reduce the protein and mRNA levels of PCNA in the pBOO bladder when compared to vehicle-treated pBOO (Fig. 8A, D-E) .
Following vehicle (DMSO) treatment, the ratio of bladder weight to body weight of pBOO animals was about 5-fold higher than vehicletreated sham-operated animals (Fig. 9 ). LY294002-treated pBOO rats had significantly smaller urinary bladder than vehicle-treated pBOO rats (Fig. 9 , p < 0.01), however, the ratio of bladder weight to body weight of pBOO animals following LY294002 treatment was still significantly higher (~3 folds) than that in LY294002-treated sham-operated rats (Fig. 9 , p < 0.01).
Discussion
The present study demonstrates that urinary bladder hypertrophy induced by 2 weeks of pBOO involves up-regulation of the protein levels of type I collagen, αSMA, and PCNA in the urinary bladder, indicating contributions of fibrosis, cellular hypertrophy, and cell hyperproliferation in bladder wall thickening. Although the protein levels of type I collagen and αSMA are increased by pBOO, their mRNA levels are not changed in the hypertrophic urinary bladder when compared to sham-operated control. This infers that the activity of protein synthesis might be up-regulated in the urinary bladder at 2 weeks of pBOO. Akt1, mTor, p70 S6K , and 4E-BP1 are major components that are involved in mRNA translation [26, 32] . At 2 weeks of pBOO, the phosphorylation levels of Akt1, mTor, p70S6K, and 4E-BP1 are increased in the urinary bladder. Suppression of PI3K, the Akt kinase, with inhibitor LY294002 reduced the phosphorylation levels of Akt1 and 4E-BP1, and the protein levels of type I collagen and αSMA. However, suppression of Akt1 with LY294002 does not inhibit PCNA expression. In the hypertrophic urinary bladder, PCNA is increased mainly in the urothelium layer but not the muscle layer. These results suggest that Akt1 prefers regulating the pathways in the detrusor muscle layer that produces type I collagen and αSMA to the pathways in the urothelium layer that produces PCNA. Inhibition of Akt by LY294002 partially reduces bladder weight caused by pBOO. Thus inhibition of Akt1-mediated protein synthesis might be necessary but not sufficient in treatment of urinary bladder hypertrophy in pBOO. The urinary bladder is made of four layers. The innermost urothelium layer, which is made of epithelium cells, acts as a permeability barrier protecting underlying tissues against noxious urine components; the next suburothelium space contains nerves, blood vessels and connective tissues; the muscular layer is called the detrusor muscle which controls the distension and contraction of the urinary bladder, and is surrounded by the outer layer, a serous membrane. Although the causes of bladder wall thickening are not clear, studies in several disease states including pBOO show that it involves one or more of the following factors: urothelial expansion, enlargement of lamina propria spaces, detrusor smooth muscle layer thickening, serous membrane inflammation, and subserous widening [3, 8, 10, 12, 31, 33, 34] . In the Fig. 1 . Validation of urinary bladder hypertrophy after pBOO. At 2 weeks after pBOO, there is an increase in the ratio of the bladder weight to body weight (A). H&E stain (B and C) shows an increase in the thickness of the detrusor wall (D). **, p < 0.01 and *, p < 0.05 vs. sham control. Bar = 200 μm. present study, type I collagen up-regulation may result in excessive deposition of fibrotic matrix which can contribute to the enlargement of lamina propria and subserous spaces in the hypertrophic urinary bladder. Up-regulation of αSMA in relative to H3 implicates cellular hypertrophy which may contribute to the thickening the detrusor muscle layers. The up-regulation of PCNA in the urothelium may contribute to urothelial hyper-proliferation thereby expansion of the mucosal folds. Therefore, pBOO-induced urinary bladder hypertrophy involves multifaceted changes at molecular level in both urothelium and smooth muscle layers.
Studies in many experimental species including rats, mice, rabbits, and guinea pigs show that fibrosis and inflammation are common factors in urinary bladder hypertrophy [11] . The cues that lead to fibrosis and inflammation in the urinary bladder are not clear, but have been suggested to involve a number of processes including but not limit to up-regulation of transforming growth factor (TGF)-β1 [35, 36] , imbalance between matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) [37] , mast cell accumulation Fig. 3 . Up-regulation of αSMA in the hypertrophic urinary bladder. The protein level of αSMA is increased in the urinary bladder by pBOO (A-B) . The mRNA level of αSMA is not changed (C). The density of smooth muscle cells in pBOO bladder is smaller than that in sham-operated control (D-F). Arrows indicate nucleuses of smooth muscle cell (D-E). *, p < 0.05 vs. sham control. [12], ATP release from serosa [38] , oxidative stress and free radical damage [39] , and up-regulation of nerve growth factor (NGF) and other growth factors [1, 36, 40] . Many of these cues are related to activation of the serine/threonine kinase Akt that serves as a central stage in signal transduction. In the present study, we show that inhibition of endogenous Akt activity partially reduces bladder hypertrophy caused by pBOO. We demonstrate that up-regulation of Akt leads to excessive protein production of type I collagen and αSMA in the hypertrophic urinary bladder, however, the increased PCNA levels in urothelium is not regulated by Akt. It is reported that at 6 weeks of pBOO, the upregulation of type I and type III collagen mRNA and protein are observed in the hypertrophic urinary bladder [9, 16] . At 2 weeks of pBOO, we only observe an up-regulation of collagen protein but not mRNA in the urinary bladder, and in the same sample we detect an Akt-independent up-regulation of PCNA mRNA levels. These results suggest that transcription and translation are two independent biological processes in the development of bladder hypertrophy following pBOO. The Akt-mediated signaling pathway regulates the translational process regardless of the changes in the transcriptional levels.
We examined two Akt isoforms, Akt1 and Akt2, and found that only Akt1 was activated in the hypertrophic urinary bladder induced by pBOO. Akt1 is originally identified as the oncogene in the transforming retrovirus [41] . The underlying mechanisms of Akt1 in regulating cell growth are attributable to its ability of preventing apoptosis [42] and enhancing protein synthesis [43] . This is true that when we inhibit Akt1, we also block the phosphorylation level of 4E-BP1, a key molecule that regulates mRNA translation. It is documented that Akt1 is a key signaling protein that leads to skeletal muscle hypertrophy [44] . In the present study, we show that inhibition of Akt1 also blocks the protein level of αSMA in the pBOO urinary bladder. αSMA composes major protein content in the cytoplasm of smooth muscle cells. We detect an up-regulation of αSMA protein in relative to nuclear protein H3 in the pBOO urinary bladder. We also observe that the distance between two nucleuses of smooth muscle cells in the pBOO bladder is larger when compared to sham-operated control. This could be due to excessive extracellular collagen deposition or smooth muscle hypertrophy. Although hyperplasia is considered as an important factor in urinary bladder hypertrophy, we fail to detect an up-regulation of PCNA in the smooth muscle layer at 2 weeks of pBOO. This does not preclude that PCNA is not changed in the smooth muscle layer at shortterm (1 week) or long-term (6 weeks) pBOO. LY294002 is a pan inhibitor of PI3K and is widely used for mechanistic studies of the PI3K-mediated signaling pathways in vivo and in vitro. The present study demonstrates that LY294002 treatment of pBOO animals reduces the elevated phosphorylation levels of Akt1 and 4E-BP1, suggesting a PI3K-dependent activation of protein synthesis in the hypertrophic urinary bladder. LY294002 treatment also nearly abrogates the protein levels of type I collagen and αSMA that is expressed by the muscle layer but barely has effects on the expression of PCNA that is expressed by the urothelial layer, suggesting that PI3K/Akt1-mediated protein synthesis are tissue/cell/molecule specific. When comparing the fold increases in the bladder weight (4-5 folds) and the thickness of the bladder muscular wall (1.6 folds) following pBOO, we conclude that the increased thickness of the bladder muscular wall that is attributed by collagen and αSMA up-regulation is, but not all factors contributing to the development of bladder organ hypertrophy. The urothelial hypertrophy governed by PCNA expression and independent of the PI3K/Akt pathway might be the major cause of the urinary bladder hypertrophy in pBOO thus LY294002 treatment only partially reduces pBOO-induced urinary bladder hypertrophy.
Bladder outlet obstruction is a urinary disorder stemming from a , and 4E-BP1 in the hypertrophic urinary bladder. Western blot with specific phospho-protein antibodies shows that the phosphorylation levels of mTOR, p70 S6K and 4E-BP1 are increased in hypertrophic urinary bladder when compared to sham control. *, p < 0.05. variety of causes such as posterior urethral valves in children ( [45, 46] , benign prostatic hyperplasia in men [47] , and urethral stricture as well as other conditions [48] . Patients with obstruction are at increased risk of urinary tract infections due to incomplete bladder emptying and postvoid residues ( [49] [50] [51] . Urinary bladder wall thickening after obstruction is considered as an effective test to evaluate the effectiveness of drug treatment [5] . Many small molecule inhibitors of the PI3K/Akt pathway have been developed and are under clinical evaluation [52] . Inhibition of the Akt1-mediated protein synthesis may be effective, at least in part, in the treatment of pBOO-induced urinary bladder hypertrophy. Fig. 9 . Induction of bladder weight in pBOO by LY294002 treatment. Vehicle treatment does not affect the increase in the ratio of bladder weight to body weight in pBOO rats when compared to vehicle-treated sham control. LY294002 (LY) treatment significantly reduced the bladder weight in pBOO rats when compared to vehicle-treated pBOO rats. The bladder weight in LY-treated pBOO rats is significantly higher than LY-treated sham control.
